MARCH 2026 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
CHMP (Committee for Medicinal Products for Human Use- EMA) March 26. Serplulimab – NSCLC EGFR/ALK/ROS1. The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a new indication for the Anti-PD-1 monoclonal antibody: serplulimab in combination with carboplatin and pemetrexed is indicated for the first-line treatment of adult non-squamous non-small cell […]